CamGene Therapeutics

Based in the UK, CamGene Therapeutics specializes in developing innovative RNA-based therapeutics aimed at addressing hearing loss through advanced delivery mechanisms, significantly enhancing the quality of life for affected individuals. CamGene Therapeutics, founded in 2023 by Arpan Desai in Cambridge, UK, is focused on creating RNA-based treatments for hearing loss. The company has completed 2 deals to date. In November 2025, CamGene Therapeutics raised an undisclosed amount of seed funding led by new investor Future Planet Capital, with participation from other new investors Eos, Cambridge Enterprise, Hex Two, LongRiver Investments, and Parkwalk Advisors.

Returning investor O2h Ventures and other unspecified investors also participated in the round. CamGene Therapeutics is focused on developing innovative RNA-based therapeutics specifically designed to address hearing loss. The core product offering revolves around lipid nanoparticle (LNP) mRNA technology, which allows for the delivery of therapeutic proteins aimed at the regeneration and protection of cochlear cells—critical components in hearing. This technology addresses the underlying cellular dysfunction that causes various types of hearing loss, providing a pathway for treatment that is currently absent in the market.

The end users of these products primarily include individuals suffering from hearing loss, with the aim of creating an accessible mass-market medicine that can significantly improve their quality of life. CamGene plans to target markets globally, including North America, Europe, and parts of Asia, thereby reaching a wide demographic of patients who currently rely on ineffective medical devices as a standard of care. CamGene's revenue model is structured around partnerships and collaborations with healthcare providers, research institutions, and potentially pharmaceutical companies as it progresses through development phases. The company engages in B2B transactions, establishing agreements with hospitals and clinics for their RNA therapeutics aimed at hearing loss.

The transaction structure includes upfront payments for access to their technology, milestone payments as products advance through clinical trials, and revenue sharing upon product commercialization. Specific pricing plans for the therapeutics are tailored to the healthcare setting; however, they are designed to be financially accessible to enhance patient reach and adoption. The flagship offerings are centered around their breakthrough encapsulated mRNA therapies, which, upon successful development and market entry, are expected to generate significant revenue streams from both direct sales and collaborative partnerships. CamGene Therapeutics plans to introduce new RNA-based products designed for hearing loss within the next two years, targeting global markets including North America, Europe, and parts of Asia.

Recent funding from O2h Ventures will be utilized to support the development of these products and to expand the company's market reach by establishing necessary partnerships within the healthcare ecosystem.